A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
N/A
The purpose of this study is to describe the reasons, therapy, and/or disea...
Status
Completed
Location
Local Institution - 0001
Start Date
2023-07-14
Trial ID
NCT05658601
Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.
N/A
The goal of this observational study is to evaluate the slowing/reduction o...
Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration
N/A
The study design matches with a multicenter observational ambispective stud...
Status
Completed
Location
Groupement des Hôpitaux de l'Institut Catholique de Lille (HICL)